Novel bioinformatic identification of differentially expressed tissue-specific and cancer-related proteins from the Human Protein Atlas for biomarker discovery
Novel bioinformatic identification of differentially expressed tissue-specific and cancer-related proteins from the Human Protein Atlas for biomarker discovery
复制标题
DOI：
10.4238/2015.may.4.14
复制
发表时间：
2015-01-01
影响因子：
0.4
通讯作者：
Liu, F. -J.
中科院分区：
文献类型：
--
作者：
Liu, X. -X.;Liu, F. -J.
肿瘤相关蛋白和组织特异性蛋白的鉴定对于研究肿瘤发生机制和发现生物标志物具有重要意义。在这里，我们进行了一个新的策略，以确定候选癌症蛋白质挖掘免疫组化蛋白质谱。利用生物信息学方法对14例正常组织和相应癌组织中具有定量值的蛋白质进行比较分析。最终结果包括鉴定组织特异性蛋白质和不同癌症类型中差异表达的蛋白质，这些蛋白质主要参与能量代谢和细胞侵袭。从组织特异性蛋白中，进一步筛选分泌蛋白和膜蛋白，并进行功能聚类。这些主要属于内源性配体、分化分子簇和溶质载体的基因家族，并且主要参与细胞运动、激素代谢、粘附和转运过程。进一步的研究是必要的，以验证本文确定的候选人，并证实所建议的丰富功能。这项研究的结果可能为研究潜在的致癌机制和发现潜在的癌症靶点提供可靠的资源，用于开发治疗靶点和早期诊断和疾病反应标志物。
Identification of cancer-associated and tissue-specific proteins is important for research on carcinogenesis mechanisms and biomarker discovery. Here we performed a new strategy to identify candidate cancer proteins by mining immunohistochemistry protein profiles. Proteins with quantitative values from 14 normal tissues and their corresponding cancer tissues were compared and analyzed using bioinformatics. The final results included identification of tissue-specific proteins and differentially expressed proteins in different cancer types that are primarily involved in energy metabolism and cell invasion. From the tissue-specific proteins, secreted and membrane proteins were further screened and functionally clustered. These primarily belonged to the gene families of endogenous ligands, cluster of differentiation molecules, and solute carriers, and were mainly involved in the processes of cell motility, hormone metabolism, adhesion, and transport. Further studies are warranted to validate the candidates identified herein and substantiate the suggested enriched functions. The results from this study might provide a reliable resource to study underlying carcinogenesis mechanisms and discover potential cancer targets for the development of therapeutic targets and of early diagnosis and disease response markers.